Periprocedural drug therapy
| Drug type | Drug | All patients (%) | Stable CAD (%) | ACS (%) | p-Value Stable CAD vs ACS | |
| Pre-PCI | APT | Clopidogrel | 1529 (53.1) | 1061 (59.2) | 468 (43.2) | <0.001 |
| Prasugrel | 328 (11.4) | 162 (9.0) | 166 (15.3) | |||
| Ticagrelor | 383 (13.3) | 156 (8.7) | 227 (20.9) | |||
| Ticlopidine | 19 (0.7) | 9 (0.5) | 10 (0.9) | |||
| Aspirin only | 316 (11.0) | 205 (11.4) | 111 (10.2) | |||
| No preloading | 302 (10.5) | 200 (11.2) | 102 (9.4) | |||
| OAC | All OAC | 54 (1.9) | 40 (2.2) | 14 (1.3) | 0.072 | |
| VKA | 33 (1.1) | 25 (1.4) | 8 (0.7) | 0.188 | ||
| NOAC, eg, rivaroxaban | 21 (0.7) | 15 (0.8) | 6 (0.5) | |||
| Post-PCI | APT | Clopidogrel | 2010 (69.9) | 1450 (80.9) | 560 (51.7) | <0.001 |
| Prasugrel | 300 (10.4) | 90 (5.0) | 210 (19.4) | |||
| Ticagrelor | 501 (17.4) | 212 (11.8) | 289 (26.7) | |||
| Aspirin only | 28 (1.0) | 16 (0.9) | 12 (1.1) | |||
| Unknown | 38 (1.3) | 25 (1.4) | 13 (1.2) | |||
ACS, acute coronary syndrome; APT, antiplatelet therapy; CAD, coronary artery disease; NOAC, new oral anticoagulative; OAC, oral anti-coagulatives; PCI, percutaneous coronary intervention; VKA, vitamin k antagonist.